JP2006515276A - 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物 - Google Patents

骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物 Download PDF

Info

Publication number
JP2006515276A
JP2006515276A JP2004546535A JP2004546535A JP2006515276A JP 2006515276 A JP2006515276 A JP 2006515276A JP 2004546535 A JP2004546535 A JP 2004546535A JP 2004546535 A JP2004546535 A JP 2004546535A JP 2006515276 A JP2006515276 A JP 2006515276A
Authority
JP
Japan
Prior art keywords
compound
bone
osteoporosis
furan derivative
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004546535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515276A5 (https=
Inventor
キム・ジョングン
キム・セウォン
オ・グィオク
コ・ソンイル
キム・ジョンヨ
イ・ビョンウィ
キム・ボムテ
イ・ヨンス
ミン・ヨンギ
パク・ノギュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2003-0072536A external-priority patent/KR100528176B1/ko
Application filed by Korea Research Institute of Chemical Technology KRICT filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of JP2006515276A publication Critical patent/JP2006515276A/ja
Publication of JP2006515276A5 publication Critical patent/JP2006515276A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C07D307/48—Furfural

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004546535A 2002-10-22 2003-10-22 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物 Pending JP2006515276A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20020064670 2002-10-22
KR10-2003-0072536A KR100528176B1 (ko) 2002-10-22 2003-10-17 골다공증 예방 및 치료효과를 갖는 퓨란 유도체 및 이를포함하는 약학적 조성물
PCT/KR2003/002231 WO2004037804A1 (en) 2002-10-22 2003-10-22 Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same

Publications (2)

Publication Number Publication Date
JP2006515276A true JP2006515276A (ja) 2006-05-25
JP2006515276A5 JP2006515276A5 (https=) 2010-03-04

Family

ID=36729279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546535A Pending JP2006515276A (ja) 2002-10-22 2003-10-22 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物

Country Status (4)

Country Link
US (1) US20060004088A1 (https=)
JP (1) JP2006515276A (https=)
AU (1) AU2003273096A1 (https=)
WO (1) WO2004037804A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1745062T3 (pl) * 2004-04-22 2014-10-31 Regado Biosciences Inc Ulepszone modulatory czynników krzepnięcia
US8247582B2 (en) * 2006-02-07 2012-08-21 Battelle Memorial Institute Esters of 5-hydroxymethylfurfural and methods for their preparation
US8293720B2 (en) * 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201270102A1 (ru) 2009-06-30 2012-08-30 Форест Лэборетериз Холдингз Лимитед Соединения алкокси-карбонил-амино-алкинил-аденозина и их производные в качестве агонистов ar
CN103040803A (zh) * 2013-01-25 2013-04-17 南通大学 5-羟甲基-2-糠醛及其衍生物在制备预防和治疗骨代谢异常疾病的药物组合物中的应用
CA2931552A1 (en) * 2013-12-19 2015-06-25 Archer Daniels Midland Company Sulfonates of furan-2,5-dimethanol and (tetrahydrofuran-2,5-diyl)dimethanol and derivatives thereof
CN106660935A (zh) * 2014-05-12 2017-05-10 微麦德斯公司 从5‑(卤甲基)糠醛产生化合物的方法
WO2016191682A1 (en) * 2015-05-28 2016-12-01 The Regents Of The University Of California Preparation of acid chlorides from 5-(chloromethyl) furfural
CN108349920A (zh) 2015-09-17 2018-07-31 微麦德斯公司 呋喃醛上的氧化化学
CN105566260B (zh) * 2015-12-03 2018-02-16 常州亚邦制药有限公司 一种呋塞米的制备方法
CN113149941A (zh) * 2020-01-22 2021-07-23 中国科学院上海药物研究所 醚类化合物及其在防治糖尿病及代谢综合征中的药学用途

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2842243A1 (de) * 1978-09-28 1980-04-10 Hoechst Ag Furan- und thiophen-carbonsaeure-derivate und verfahren zu ihrer herstellung
JPS56135482A (en) * 1980-03-26 1981-10-22 Noguchi Kenkyusho Production of 5-methyl-2-frufural
JPS56138177A (en) * 1980-03-28 1981-10-28 Noguchi Kenkyusho Preparation of 5-acyloxymethylfurfural
JPS59227847A (ja) * 1983-06-09 1984-12-21 Toyama Chem Co Ltd Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
JPS62175458A (ja) * 1985-11-21 1987-08-01 ビ−チヤム・グル−プ・ピ−エルシ− 新規化合物、その製法及びそれを含む医薬組成物
JPH0285211A (ja) * 1988-03-15 1990-03-26 Tsumura & Co 新規フェネチルアルコール配糖体および免疫抑制剤
JPH0558893A (ja) * 1991-02-08 1993-03-09 Pfizer Inc コレステロール低下組成物
JPH0625205A (ja) * 1992-02-07 1994-02-01 Roussel Uclaf フラン又はチオフェンアルコールから誘導される新規なピレスロイドエステル、それらの製造法及び有害生物駆除剤としての用途
JPH06502408A (ja) * 1990-10-12 1994-03-17 セントル・アンテルナショナル・ドゥ・ルシェルシェ・デルマトロジク・ガルデルマ（セイエレデー・ガルデルマ） ジ芳香族化合物、ならびに人間および動物用医薬ならびに化粧品におけるそれらの用途
JPH07138187A (ja) * 1993-11-16 1995-05-30 Nippon Ham Kk 経口免疫寛容原、経口慢性関節リウマチ治療剤及び機能性食品
JPH0959176A (ja) * 1995-06-13 1997-03-04 Nippon Ham Kk 経口慢性関節リウマチ治療剤及び機能性食品
JPH11139979A (ja) * 1997-11-07 1999-05-25 Nitto Denko Corp 免疫系抑制用組成物
WO1999026923A1 (en) * 1997-11-20 1999-06-03 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
JPH11279204A (ja) * 1998-03-27 1999-10-12 Sumitomo Forestry Co Ltd 免疫抑制剤
JP2000038343A (ja) * 1998-05-20 2000-02-08 Hayashibara Biochem Lab Inc 抗骨粗鬆症剤
JP2001064263A (ja) * 1999-07-21 2001-03-13 F Hoffmann La Roche Ag トリアゾール及びイミダゾール誘導体
WO2002007718A1 (en) * 2000-07-21 2002-01-31 Hormos Medical Corporation Method for the treatment of climacteric disorders in women during or after the menopause
JP2006508079A (ja) * 2002-10-09 2006-03-09 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052507A (https=) * 1963-06-26
US3903293A (en) * 1970-04-23 1975-09-02 Basf Ag Fungicidal substituted furancarboxylic acid cycloalkylamide
US3778512A (en) * 1970-06-23 1973-12-11 Velsicol Chemical Corp Fungicidal method utilizing furancarboxamides
JP2575823B2 (ja) * 1988-06-29 1997-01-29 三井東圧化学株式会社 αーアミノアセトニトリル塩酸塩類の製造方法
JPH06128246A (ja) * 1992-10-20 1994-05-10 Mita Ind Co Ltd ヒドラゾン系化合物およびそれを用いた電子写真感光体

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2842243A1 (de) * 1978-09-28 1980-04-10 Hoechst Ag Furan- und thiophen-carbonsaeure-derivate und verfahren zu ihrer herstellung
JPS56135482A (en) * 1980-03-26 1981-10-22 Noguchi Kenkyusho Production of 5-methyl-2-frufural
JPS56138177A (en) * 1980-03-28 1981-10-28 Noguchi Kenkyusho Preparation of 5-acyloxymethylfurfural
JPS59227847A (ja) * 1983-06-09 1984-12-21 Toyama Chem Co Ltd Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
JPS62175458A (ja) * 1985-11-21 1987-08-01 ビ−チヤム・グル−プ・ピ−エルシ− 新規化合物、その製法及びそれを含む医薬組成物
JPH0285211A (ja) * 1988-03-15 1990-03-26 Tsumura & Co 新規フェネチルアルコール配糖体および免疫抑制剤
JPH06502408A (ja) * 1990-10-12 1994-03-17 セントル・アンテルナショナル・ドゥ・ルシェルシェ・デルマトロジク・ガルデルマ（セイエレデー・ガルデルマ） ジ芳香族化合物、ならびに人間および動物用医薬ならびに化粧品におけるそれらの用途
JPH0558893A (ja) * 1991-02-08 1993-03-09 Pfizer Inc コレステロール低下組成物
JPH0625205A (ja) * 1992-02-07 1994-02-01 Roussel Uclaf フラン又はチオフェンアルコールから誘導される新規なピレスロイドエステル、それらの製造法及び有害生物駆除剤としての用途
JPH07138187A (ja) * 1993-11-16 1995-05-30 Nippon Ham Kk 経口免疫寛容原、経口慢性関節リウマチ治療剤及び機能性食品
JPH0959176A (ja) * 1995-06-13 1997-03-04 Nippon Ham Kk 経口慢性関節リウマチ治療剤及び機能性食品
JPH11139979A (ja) * 1997-11-07 1999-05-25 Nitto Denko Corp 免疫系抑制用組成物
WO1999026923A1 (en) * 1997-11-20 1999-06-03 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
JPH11279204A (ja) * 1998-03-27 1999-10-12 Sumitomo Forestry Co Ltd 免疫抑制剤
JP2000038343A (ja) * 1998-05-20 2000-02-08 Hayashibara Biochem Lab Inc 抗骨粗鬆症剤
JP2001064263A (ja) * 1999-07-21 2001-03-13 F Hoffmann La Roche Ag トリアゾール及びイミダゾール誘導体
WO2002007718A1 (en) * 2000-07-21 2002-01-31 Hormos Medical Corporation Method for the treatment of climacteric disorders in women during or after the menopause
JP2006508079A (ja) * 2002-10-09 2006-03-09 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド

Also Published As

Publication number Publication date
US20060004088A1 (en) 2006-01-05
AU2003273096A8 (en) 2004-05-13
AU2003273096A1 (en) 2004-05-13
WO2004037804A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP2762522B2 (ja) 血管新生阻害剤
JPH085780B2 (ja) 変形性関節症治療剤
JP2006515276A (ja) 骨粗鬆症の予防及び治療効果を有するフラン誘導体並びにこれを含む薬学的組成物
JP5957058B2 (ja) 骨系疾患の予防・治療用の、ウルムスワリチアーナから分離した新規なフラボノール化合物、生物活性抽出物／フラクション、及びその化合物
US20080221205A1 (en) Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
KR101656834B1 (ko) 콜포신 다로페이트를 포함하는 골 질환의 예방 또는 치료용 조성물
KR100624238B1 (ko) 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
CN108785290B (zh) 龙血竭查尔酮类有效成分在制备药物中的用途
KR101481709B1 (ko) Ｓａｃ－１００４ 복합체를 유효성분으로 포함하는 발기부전 예방 또는 치료용 조성물
KR20060047787A (ko) 바쿠치올을 포함하는 여성 골다공증 치료용 약제학적조성물
KR101305555B1 (ko) 신이 활성 화합물들을 유효성분으로 함유하는 골질환 예방 및 치료용 조성물
CN115671096A (zh) 6-甲氧基当归素及其结构类似物的用途
KR102063962B1 (ko) 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
CN114129565A (zh) 组蛋白甲基转移酶ezh2抑制剂在促使骨代谢进入高转换以修复骨缺损产品中的应用
CN101845052B (zh) 一类含氮杂环的噻吩并吡啶酮衍生物、其制备方法和用途
NZ539141A (en) Control of cancer with annonaceous extracts
CN116098904A (zh) 一种酰基哌嗪类化合物在制备预防或治疗代谢综合征药物中的用途
CN119367365B (zh) 一种用于防治糖尿病的联合用药物
KR101841541B1 (ko) 황기 추출물 및 지치 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약학적 조성물
KR20200038411A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학 조성물
KR100738230B1 (ko) 메톡시아크릴레이트계 화합물을 포함하는, 골다공증 예방 또는 치료용 조성물
KR100500543B1 (ko) 다이하이드로 벤조퓨란구조를 골격으로 하는 카이네이즈저해 화합물
JPH0629184B2 (ja) 骨粗鬆症治療剤
KR20050082447A (ko) 테트라하이드로베르베린을 유효성분으로 함유하는 당뇨예방 및 치료제 조성물
CN117959269A (zh) pp’-DDE及其同系物在制备治疗骨质疏松药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060328

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070109

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100108

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101214